Sec Form 4 Filing - Boxmeyer Kathryn M. @ Paratek Pharmaceuticals, Inc. - 2014-10-30

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Boxmeyer Kathryn M. 2. Issuer Name and Ticker or Trading Symbol Paratek Pharmaceuticals, Inc. [ PRTK] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) See Remarks (Last) (First) (Middle) C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET 3. Date of Earliest Transaction (MM/DD/YY) 10/30/2014 (Street) BOSTON, MA02111 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 10/30/2014 J( 1 ) 50,817 A 50,817 D Common Stock 10/30/2014 J( 1 ) 45 A 45 I Jointly with spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options $ 4.3 10/30/2014 J( 2 )( 3 ) 6,272 ( 2 ) 06/28/2024 Common Stock 6,272 ( 2 ) ( 3 ) 6,272 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Boxmeyer Kathryn M. C/O PARATEK PHARMACEUTICALS, INC. 75 KNEELAND STREET BOSTON, MA02111 See Remarks Signatures /s/ Kathryn M. Boxmeyer 11/03/2014 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Shares were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 30, 2014, by and among the Issuer, Tigris Merger Sub, Inc., Tigris Acquisition Sub, LLC and a Delaware corporation then known as Paratek Pharmaceuticals, Inc. (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock of the corporation then known as Paratek Pharmaceuticals, Inc. ("Old Paratek") was converted into 0.0675 shares of the Issuer's common stock. ( 2 )On June 29, 2014, Reporting Person was granted an option to purchase 92,920 shares of the common stock of Old Paratek under Old Paratek's 2014 Equity Incentive Plan at an exercise price of $0.29 per share. Pursuant to the Merger Agreement, these options were converted into options to purchase 6,272 shares of the Issuer's common stock at a per share exercise price of $4.30.As of the date of the closing of the Merger Agreement, options with respect to 1255 underlying shares were fully vested and, subject generally to the Reporting Person's continued employment, another 13.35% of the option grant, or 837 shares, will become vested and exercisable on the last date of each month commencing on October 31, 2014 and ending on December 31, 2014. (continued in Footnote 3) ( 3 )Thereafter, subject to the Reporting Person's continued service as a consultant, another 6.66% of the option grant, or 418 shares, will become vested and exercisable on the last date of each month commencing on January 31, 2015, provided that only 416 shares shall vest on June 30, 2015.

Remarks: Vice President and Interim Chief Financial Officer

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.